Project Grant R21MH135232
- This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $429,000.00 in funding to Thomas Jefferson University to conduct research on cell-type specific analysis of Src kinase-NMDA receptor complexes in schizophrenia. The goal of this 2-year project is to determine how Src kinase-mediated NMDA receptor signaling alterations are distinctly manifested in pyramidal neurons versus interneurons in the...
- This federal Project Grant award of $647,833 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), supports research conducted by Northwestern University to investigate cellular mechanisms underlying excitation/inhibition imbalance in the medial prefrontal cortex as a convergent pathogenic mechanism across genetic mouse models relevant to schizophrenia. The key research objectives are to: 1) determine the reversal potential of the...
- This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $128,000.00 to the Boston VA Research Institute, Inc. to investigate the spectral components of abnormal spontaneous gamma activity in schizophrenia and translational mouse models. The research aims to better understand the neural mechanisms underlying spontaneous gamma activity, which has been used as an index of excitation-inhibition...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $433,125 Project Grant to the University of California, Los Angeles to investigate inter-brain synchrony as a neural mechanism underlying social connection in individuals with schizophrenia. The two-year project, which commenced September 1, 2025 and concludes August 31, 2027, under the Mental Health Research Grants program (CFDA 93.242), represents the first direct investigation of inter-brain synchrony in...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a $1,504,616 Project Grant on June 12, 2025, under the Mental Health Research Grants program (CFDA 93.242) to investigate the relationship between N-acetyl-aspartyl-glutamate (NAAG) and memory deficits in schizophrenia patients in mid- to late-life. The research addresses a critical gap in understanding cognitive dysfunction, which is a core feature of schizophrenia that...
- Federal Project Grant Award Summary Vanderbilt University received a $217,818 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded September 9, 2025, with a completion date of September 8, 2027. The award funds research investigating metabotropic glutamate receptor (mGlu) signaling, specifically Group III mGlu4/7 receptors, as potential therapeutic targets for modulating glutamatergic synaptic transmission in...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a Project Grant of $197,640 under the Mental Health Research Grants program (CFDA 93.242), effective September 1, 2025 through August 31, 2030. This award supports an early-career investigator's research into the functional consequences of schizophrenia-associated genetic variants in GRIA3, a gene encoding the GluA3 subunit of the AMPA receptor...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Leland Stanford Junior University a Project Grant totaling $160,272 under the Mental Health Research Grants program (CFDA 93.242) for the period of June 1, 2025, through May 31, 2027. This research project, titled "Theta Burst Modulation of Hippocampal-Cortical Rhythms in Schizophrenia," investigates whether connectivity-guided theta burst stimulation (TBS) can alter hippocampal neural activity and...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Massachusetts General Hospital a five-year Mentored Research Scientist Development Award totaling $182,851 under the Mental Health Research Grants program (CFDA 93.242), effective September 19, 2025 through August 31, 2030. This project grant supports research investigating deficient memory replay as a potentially treatable mechanism underlying impaired sleep-dependent memory consolidation (SDMC) in...
- Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $832,307 Project Grant to The Regents of the University of California, San Francisco on April 24, 2026, under the Mental Health Research Grants program (CFDA 93.242). This award funds basic neuroscience research investigating the genetic control and developmental mechanisms of basal telencephalic structures, specifically examining how the medial ganglionic eminence (MGE) generates gamma-aminobutyric acid (GABA)ergic...
DISTINCT NMDA RECEPTOR SIGNALING DOMAINS REGULATE HIPPOCAMPAL NETWORK DYNAMICS - PROJECT SUMMARY/ABSTRACT SCHIZOPHRENIA IS CHARACTERIZED BY DISCORDANT THOUGHT PROCESSES, PERCEPTIONS, EMOTIONAL RESPONSIVENESS, AND SOCIAL INTERACTIONS IMPACTING UP TO 0.7 % OF THE US POPULATION (NATIONAL INSTITUTE OF MENTAL HEALTH, HEALTH STATISTICS). WHILE RATES OF OCCURRENCE ARE LOW, SCHIZOPHRENIA RANKS IN THE TOP FIFTEEN LEADING CAUSES OF WORK DISABILITY WORLDWIDE DUE TO THE SEVERITY OF THE SYMPTOMS. FIRST EPISODES OF SCHIZOPHRENIA TYPICALLY OCCUR IN THE LATE ADOLESCENCE TO EARLY ADULTHOOD. IT IS BELIEVED THAT INTERACTIONS BETWEEN GENETIC FACTORS AND AVERSIVE EARLY LIFE EXPERIENCES LEAD TO ABNORMAL BRAIN DEVELOPMENT WHICH PRODUCES THE SCHIZOPHRENIA SYMPTOMS. WHILE WIDESPREAD CHANGES IN THE BRAINS OF SCHIZOPHRENIC PATIENTS HAVE BEEN DOCUMENTED, IT IS THOUGHT THAT THE COGNITIVE DISORGANIZATION RELIES ON PATHOLOGICAL PROCESSES WITHIN THE HIPPOCAMPUS. AS EVIDENCE, ABERRANT NETWORK OSCILLATIONS IN THE HIPPOCAMPUS IN ASSOCIATION WITH A SELECTIVE SPATIAL MEMORY DEFICIT ARE PROMINENT IN SCHIZOPHRENIC PATIENTS. WITHIN THE N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) HYPOFUNCTION MODEL OF SCHIZOPHRENIA, GLUN2B SUBNITS HAVE BEEN IMPLICATED IN CHANGES IN THETA AND SLOW GAMMA OSCILLATIONS, CROSS FREQUENCY COUPING, AND IMPAIRED SPATIAL MEMORY. HOWEVER, THIS SITUATION IS MADE MORE COMPLEX BY THE FACT THAT GLUN2 SUBUNITS REGULATE IONOTROPIC AND DIRECT INTRACELLULAR SIGNALING AND THESE FACTORS HAVE NOT BEEN ADDRESSED FULLY WITH RESPECT TO THE REGULATION OF NETWORK OSCILLATIONS AND MEMORY RETRIEVAL. WE CREATED TRANSGENIC MICE EXPRESSING CHIMERIC GLUN2 SUBUNITS IN THE FOREBRAIN TO SEPARATE THE IONOTROPIC AND DIRECT INTRACELLULAR SIGNALING PROCESSES DOWNSTREAM FROM NMDAR ACTIVATION AND DISCOVERED THAT HEIGHTENED GLUN2B- TYPE INTRACELLULAR SIGNALING ENHANCES LONG-TERM SPATIAL, BUT NOT NON-SPATIAL MEMORY PERFORMANCE. SINCE SLOW GAMMA OSCILLATIONS IN THE HIPPOCAMPUS PROVIDE THE FUNCTIONAL NETWORK ORGANIZATION FOR SPATIAL MEMORY RETRIEVAL, IT IS POSSIBLE THAT GLUN2B-TYPE INTRACELLULAR SIGNALING REGULATES SLOW GAMMA OSCILLATIONS TO MEDIATE ITS EFFECTS ON LONG-TERM SPATIAL MEMORY. WE PROPOSE THAT INAPPROPRIATE GLUN2B-TYPE CTD SIGNALING IS A CRITICAL FACTOR IN THE ALTERATIONS IN SLOW GAMMA OSCILLATIONS AND SPATIAL MEMORY IN SCHIZOPHRENIA. WE WILL TEST THIS IDEA AND EXTEND THE QUESTION TO SPECIFIC SYNAPSES BY ANALYZING THETA AND SLOW GAMMA OSCILLATIONS, CROSS FREQUENCY COUPLING, AND SPATIAL MEMORY PERFORMANCE IN TRANSGENIC MICE EXPRESSING CHIMERIC GLUN2 SUBUNITS IN THE FOREBRAIN OR LIMITED TO HIPPOCAMPAL PRINCIPAL CELLS OR PARVALBUMIN-POSITIVE INTERNEURONS. WE PREDICT THAT HEIGHTENED GLUN2B-TYPE CTD SIGNALING AT EXCITATORY SYNAPSES ONTO PRINCIPAL CELLS OR INTERNEURONS WILL ACCENTUATE SLOW GAMMA FUNCTION DURING PLANNING OF PATHS TO KNOW GOAL LOCATIONS AND IMPROVE SPATIAL MEMORY. THESE FINDINGS WOULD SUPPORT GLUN2B-TYPE CTD SIGNALING AS A POWERFUL FACTOR IN THE REGULATION OF HIPPOCAMPAL NETWORK DYNAMICS AND SPATIAL MEMORY. OUTCOMES FROM THIS STUDY WILL TRANSFORM OUR UNDERSTANDING OF THE NEUROBIOLOGICAL BASES OF SCHIZOPHRENIA AND PROVIDE A NOVEL FRAMEWORK FOR FUTURE RESEARCH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 5/15/26 | ||
| Not listed | $191.4k | 7/14/25 | ||
| Not listed | $231.5k | 7/26/24 |